Canada
· Delayed Price · Currency is CAD Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of CAD 160.37 million. The enterprise value is 187.59 million.
| Market Cap | 160.37M |
| Enterprise Value | 187.59M |
Important Dates
The next estimated earnings date is Monday, January 26, 2026.
| Earnings Date | Jan 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cannara Biotech has 94.90 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 94.90M |
| Shares Outstanding | 94.90M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 0.23% |
| Float | 44.76M |
Valuation Ratios
The trailing PE ratio is 12.07 and the forward PE ratio is 9.94.
| PE Ratio | 12.07 |
| Forward PE | 9.94 |
| PS Ratio | 1.50 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | 11.74 |
| P/OCF Ratio | 8.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.62, with an EV/FCF ratio of 13.74.
| EV / Earnings | 14.35 |
| EV / Sales | 1.75 |
| EV / EBITDA | 6.62 |
| EV / EBIT | 8.66 |
| EV / FCF | 13.74 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.40 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.47 |
| Debt / FCF | 3.05 |
| Interest Coverage | 5.75 |
Financial Efficiency
Return on equity (ROE) is 13.75% and return on invested capital (ROIC) is 9.67%.
| Return on Equity (ROE) | 13.75% |
| Return on Assets (ROA) | 8.37% |
| Return on Invested Capital (ROIC) | 9.67% |
| Return on Capital Employed (ROCE) | 16.11% |
| Revenue Per Employee | 237,174 |
| Profits Per Employee | 28,930 |
| Employee Count | 452 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.32 |
Taxes
In the past 12 months, Cannara Biotech has paid 5.02 million in taxes.
| Income Tax | 5.02M |
| Effective Tax Rate | 27.74% |
Stock Price Statistics
The stock price has increased by +119.48% in the last 52 weeks. The beta is 0.32, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +119.48% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 50.19 |
| Average Volume (20 Days) | 60,485 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of CAD 107.20 million and earned 13.08 million in profits. Earnings per share was 0.14.
| Revenue | 107.20M |
| Gross Profit | 47.10M |
| Operating Income | 21.66M |
| Pretax Income | 18.10M |
| Net Income | 13.08M |
| EBITDA | 28.06M |
| EBIT | 21.66M |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 14.36 million in cash and 41.58 million in debt, giving a net cash position of -27.22 million or -0.29 per share.
| Cash & Cash Equivalents | 14.36M |
| Total Debt | 41.58M |
| Net Cash | -27.22M |
| Net Cash Per Share | -0.29 |
| Equity (Book Value) | 102.22M |
| Book Value Per Share | 1.12 |
| Working Capital | 47.96M |
Cash Flow
In the last 12 months, operating cash flow was 20.01 million and capital expenditures -6.36 million, giving a free cash flow of 13.65 million.
| Operating Cash Flow | 20.01M |
| Capital Expenditures | -6.36M |
| Free Cash Flow | 13.65M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 43.94%, with operating and profit margins of 20.20% and 12.20%.
| Gross Margin | 43.94% |
| Operating Margin | 20.20% |
| Pretax Margin | 16.88% |
| Profit Margin | 12.20% |
| EBITDA Margin | 26.18% |
| EBIT Margin | 20.20% |
| FCF Margin | 12.74% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | 8.15% |
| FCF Yield | 8.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.35 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 7 |